

Datasheet for ABIN7448155
CD24 Protein-VLP (AA 26-57)



[Go to Product page](#)

1 Image

Overview

Quantity:	100 µg
Target:	CD24
Protein Characteristics:	AA 26-57
Origin:	Cynomolgus
Source:	HEK-293 Cells
Protein Type:	VLP
Biological Activity:	Active
Application:	ELISA, Immunogen (Imm), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Product Details

Purpose:	Cynomolgus CD24 Protein-VLP
Sequence:	Ser26-Gly57
Characteristics:	Recombinant Cynomolgus CD24 Protein-VLP is expressed from HEK293. It contains Ser26-Gly57.
Purity:	> 90 % as determined by HPLC
Sterility:	0.22 µm filtered
Endotoxin Level:	Less than 1EU per µg by the LAL method.

Target Details

Target:	CD24
---------	------

Target Details

Alternative Name: [CD24 \(CD24 Products\)](#)

Background: CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.

Molecular Weight: 3.8 kDa.

NCBI Accession: [XP_015304503](#)

Pathways: [Regulation of Leukocyte Mediated Immunity](#), [Positive Regulation of Immune Effector Process](#), [Activated T Cell Proliferation](#)

Application Details

Application Notes:

- Antibody Discovery: Immunization, Screening, Functional Characterization
- Affinity determination: ELISA, SPR
- In vivo pharmacokinetic analysis
- CMC method development
- CAR-T Positive Rate Detection
- Blood sample determination: ELISA

Comment: Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to

Application Details

target the specific antigen displayed on the surface of the engineered VLPs.

Restrictions: For Research Use only

Handling

Format: Liquid


Buffer: Supplied as 0.22µm filtered solution in PBS (pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.

Storage: -80 °C

Storage Comment: Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Images



SDS-PAGE

Image 1. Cynomolgus CD24 VLP on Tris-Bis PAGE under reduced conditions. The purity is greater than 95 % .